Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Liver Cirrhosis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 190 articles:
HTML format
Text format



Single Articles


    July 2019
  1. MORAIS R, Liberal R, Santos A, Pita I, et al
    Another clinical unmet need in liver patients: Multidrug resistant bacteria in decompensated cirrhosis.
    J Hepatol. 2019 Jul 27. pii: S0168-8278(19)30357.
    PubMed     Text format    


  2. HERNANDEZ-TEJERO M, Triolo M, Fernandez J
    Reply to: "Another clinical unmet need in liver patients: Multidrug-resistant bacteria in decompensated cirrhosis".
    J Hepatol. 2019 Jul 24. pii: S0168-8278(19)30403.
    PubMed     Text format    


  3. REVERTER E, Cirera I, Albillos A, Debernardi-Venon W, et al
    The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery.
    J Hepatol. 2019 Jul 19. pii: S0168-8278(19)30415.
    PubMed     Text format     Abstract available


  4. LOGLIO A, Ferenci P, Colonia Uceda Renteria S, Tham CYL, et al
    Excellent safety and effectiveness of high dose myrcludex-b monotherapy administered for 48 weeks in hdv related compensated cirrhosis: a case report of three patients.
    J Hepatol. 2019 Jul 11. pii: S0168-8278(19)30411.
    PubMed     Text format     Abstract available


  5. SORRIBAS M, Jakob MO, Yilmaz B, Li H, et al
    FxR-modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    J Hepatol. 2019 Jul 8. pii: S0168-8278(19)30389.
    PubMed     Text format     Abstract available


    June 2019
  6. MAJUMDAR A, Roberts SK, Pilcher D
    Are liver transplant centres critical for the critically ill patient with cirrhosis?
    J Hepatol. 2019 Jun 21. pii: S0168-8278(19)30288.
    PubMed     Text format    


  7. PRODEAU M, Drumez E, Duhamel A, Vibert E, et al
    An Ordinal Model to Predict the Risk of Symptomatic Liver Failure in Patients with Cirrhosis undergoing Hepatectomy.
    J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30346.
    PubMed     Text format     Abstract available


  8. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response".
    J Hepatol. 2019 Jun 7. pii: S0168-8278(19)30280.
    PubMed     Text format    


    May 2019
  9. IOANNOU GN, Green P, Kerr KF, Berry K, et al
    Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
    J Hepatol. 2019 May 27. pii: S0168-8278(19)30291.
    PubMed     Text format     Abstract available


  10. POL S, Fontaine H, Carrat F
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response.
    J Hepatol. 2019 May 23. pii: S0168-8278(19)30186.
    PubMed     Text format    


    April 2019
  11. CABIBBO G, Celsa C, Calvaruso V, Petta S, et al
    Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30221.
    PubMed     Text format     Abstract available


    March 2019
  12. FRANCOZ C, Sola E
    Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter.
    J Hepatol. 2019 Mar 1. pii: S0168-8278(19)30118.
    PubMed     Text format    


    February 2019
  13. HERNANDEZ-GEA V, Gottardi A, Leebeek FWG, Rautou PE, et al
    Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis.
    J Hepatol. 2019 Feb 26. pii: S0168-8278(19)30130.
    PubMed     Text format     Abstract available


  14. DEVARBHAVI H, Asrani SK, Kamath PS
    Reply to: "Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia".
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30066.
    PubMed     Text format    


  15. SINGH SP, Panigrahi S, Mishra D, Khatua CR, et al
    Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia.
    J Hepatol. 2019 Feb 16. pii: S0168-8278(19)30012.
    PubMed     Text format    


    January 2019
  16. SOLA E, Sole C, Gines P
    Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out...".
    J Hepatol. 2019 Jan 30. pii: S0168-8278(18)32646.
    PubMed     Text format    


  17. FERRARESE A, Feltracco P, Barbieri S, Cillo U, et al
    Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32389.
    PubMed     Text format    


  18. VAN DER MERWE S, Laleman W, Langouche L, Meersseman P, et al
    Reply to: "Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF".
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30007.
    PubMed     Text format    


  19. SINGH V, Singh A, Agarwal R
    Midodrine and albumin in decompensated cirrhosis: Down but not out....
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32540.
    PubMed     Text format    


  20. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015.
    PubMed     Text format     Abstract available


  21. GRANCINI V, Trombetta M, Lunati ME, Boselli ML, et al
    Central role of the beta-cell in driving regression of diabetes after liver transplantation in cirrhotic patients.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30028.
    PubMed     Text format     Abstract available


  22. YOO JJ, Kim SG, Kim YS, Lee B, et al
    Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30004.
    PubMed     Text format     Abstract available


  23. TISCHENDORF M, Fuchs A, Zeuzem S, Lange CM, et al
    Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(18)32570.
    PubMed     Text format    


    December 2018
  24. BOEREKAMPS A, Vanwolleghem T, van der Valk M, van den Berk GE, et al
    8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32516.
    PubMed     Text format    


    November 2018
  25. STAMM LM, Brainard DM, McHutchison JG
    Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Nov 13. pii: S0168-8278(18)32528.
    PubMed     Text format    



  26. Reply to: "Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018".
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32529.
    PubMed     Text format    


  27. OTETE H, Deleuran T, Fleming KM, Card T, et al
    Reply to: "Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?"
    J Hepatol. 2018 Nov 10. pii: S0168-8278(18)32459.
    PubMed     Text format    


  28. FERNANDEZ J, Prado V, Trebicka J, Amoros A, et al
    Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.
    J Hepatol. 2018 Nov 1. pii: S0168-8278(18)32511.
    PubMed     Text format     Abstract available


    October 2018
  29. ZHAO LY, Luo YJ, Zhu J, Liu HY, et al
    Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?
    J Hepatol. 2018 Oct 31. pii: S0168-8278(18)32386.
    PubMed     Text format    


  30. KIM HY, So YH, Kim W, Ahn DW, et al
    Noninvasive Response Prediction in Prophylactic Carvedilol Therapy for Cirrhotic Patients with Esophageal Varices.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32502.
    PubMed     Text format     Abstract available


  31. D'AMICO G, Bataller R
    Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Oct 11. pii: S0168-8278(18)32447.
    PubMed     Text format    


  32. O'BRIEN A, Kamath PS, Trotter J
    MACHT - Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list.
    J Hepatol. 2018 Oct 9. pii: S0168-8278(18)32444.
    PubMed     Text format    


  33. GIANNINI EG, Bodini G, Furnari M, Marabotto E, et al
    NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis.
    J Hepatol. 2018;69:972-973.
    PubMed     Text format    


  34. DE FRANCHIS R, Krag A
    Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy?
    J Hepatol. 2018;69:769-771.
    PubMed     Text format    


    September 2018
  35. LOW JTS, Rohde G, Pittordou K, Candy B, et al
    Supportive and palliative care in people with cirrhosis: international systematic review of the perspective of patients, family members and health professionals.
    J Hepatol. 2018 Sep 19. pii: S0168-8278(18)32381.
    PubMed     Text format     Abstract available


  36. FERNANDEZ J, Saliba F
    Liver transplantation in patients with ACLF and multiple organ failure: Time for priority after initial stabilization.
    J Hepatol. 2018 Sep 18. pii: S0168-8278(18)32372.
    PubMed     Text format    


  37. SHEARER J, Chizhande D, Jones R, Rowe IA, et al
    Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease.
    J Hepatol. 2018 Sep 8. pii: S0168-8278(18)32282.
    PubMed     Text format    


  38. GUSTOT T, Moreau R
    Acute-on-Chronic Liver Failure vs. Traditional Acute Decompensation of Cirrhosis.
    J Hepatol. 2018 Sep 6. pii: S0168-8278(18)32370.
    PubMed     Text format     Abstract available


  39. PETTA S, Sebastiani G, de Ledinghen V
    Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease".
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32300.
    PubMed     Text format    


  40. MERLI M, Durand F
    Muscle mass vs. adipose tissue to predict outcome in cirrhosis: Which matters and in which patients?
    J Hepatol. 2018;69:567-569.
    PubMed     Text format    


    August 2018

  41. Corrigendum to "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis" [J Hepatol 69 (2018) 406-460].
    J Hepatol. 2018 Aug 29. pii: S0168-8278(18)32290.
    PubMed     Text format    


  42. YOUNOSSI Z, Stepanova M, Sanyal AJ, Harrison SA, et al
    The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32295.
    PubMed     Text format     Abstract available


  43. ANDRADE F, Shukla A, Bureau C, Senzolo M, et al
    Pregnancy in Idiopathic Non-Cirrhotic Portal Hypertension: A Multicentric Study on Maternal and Fetal Management and Outcome.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32286.
    PubMed     Text format     Abstract available


  44. CLARK VC, Marek G, Liu C, Collinsworth A, et al
    Clinical and Histologic Features of Adults with Alpha-1 Antitrypsin Deficiency in a Non-Cirrhotic Cohort.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32284.
    PubMed     Text format     Abstract available


  45. SOLA E, Sole C, Simon-Talero M, Martin-Llahi M, et al
    MIDODRINE &ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32285.
    PubMed     Text format     Abstract available


  46. GANNE-CARRIE N, Chaffaut C, Bourcier V, Archambeaud I, et al
    Estimate of hepatocellular carcinoma's incidence in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32278.
    PubMed     Text format     Abstract available


    July 2018
  47. MAROT A, Henrion J, Knebel JF, Deltenre P, et al
    Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32160.
    PubMed     Text format    


  48. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32168.
    PubMed     Text format    


  49. LAI SW, Lin CL, Liao KF
    Association between cirrhosis and hip fracture in older people in a population-based cohort study.
    J Hepatol. 2018 Jul 2. pii: S0168-8278(18)32060.
    PubMed     Text format    


    June 2018
  50. TANDON P, Ismond KP, Riess K, Duarte-Rojo A, et al
    Exercise in Cirrhosis: Translating evidence and experience to practice.
    J Hepatol. 2018 Jun 28. pii: S0168-8278(18)32170.
    PubMed     Text format     Abstract available


  51. YU JJ, Li JD, Xu XF, Shen F, et al
    Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 Jun 8. pii: S0168-8278(18)32061.
    PubMed     Text format    


  52. BRADLEY CR, Cox EF, Scott RA, James MW, et al
    Multi organ assessment of Compensated Cirrhosis Patients using quantitative Magnetic Resonance Imaging.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32122.
    PubMed     Text format     Abstract available


  53. TURCO L, Garcia-Tsao G, Rossi R, Villa E, et al
    Reply to "The Relationship of Hyperdynamic Circulation and Cardiodynamic States in Cirrhosis".
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32101.
    PubMed     Text format    


    May 2018
  54. SUNDARAM V, Goldberg DS, Jalan R
    Author response: Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 May 31. pii: S0168-8278(18)32100.
    PubMed     Text format    


  55. PETTA S, Sebastiani G, Bugianesi E, Vigano M, et al
    Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32065.
    PubMed     Text format     Abstract available


  56. ALVARADO E, Garcia-Guix M, Mirabet S, Villanueva C, et al
    The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis.
    J Hepatol. 2018 May 18. pii: S0168-8278(18)32044.
    PubMed     Text format    


    April 2018
  57. MOLLER S, Lee SS
    Cirrhotic cardiomyopathy.
    J Hepatol. 2018 Apr 28. pii: S0168-8278(18)30017.
    PubMed     Text format    


  58. EBADI M, Tandon P, Moctezuma-Velazquez C, Ghosh S, et al
    Low Subcutaneous Adiposity Associates with Higher Mortality in Female Patients with Cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32026.
    PubMed     Text format     Abstract available


  59. SUNDARAM V, Jalan R, Ahn JC, Charlton MR, et al
    Class III obesity is a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32027.
    PubMed     Text format     Abstract available


  60. OTETE H, Deleuran T, Fleming KM, Card TR, et al
    Hip fracture risk in patients with alcoholic cirrhosis: a population-based study using English and Danish data.
    J Hepatol. 2018 Apr 16. pii: S0168-8278(18)31978.
    PubMed     Text format     Abstract available



  61. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 10. pii: S0168-8278(18)31966.
    PubMed     Text format    


  62. LUCIDI C, Lattanzi B, Riggio O, Merli M, et al
    May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?
    J Hepatol. 2018 Apr 4. pii: S0168-8278(18)30213.
    PubMed     Text format    


  63. VAN VUGT JLA, Alferink LJM, Buettner S, Metselaar HJ, et al
    Reply to: "May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?" and "Has the time come for using MELD-Sarcopenia score?"
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30212.
    PubMed     Text format    


    March 2018
  64. PUOTI M, Foster GR, Wang S, Mutimer D, et al
    High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30165.
    PubMed     Text format     Abstract available


  65. FORREST EH, Atkinson SR, Richardson P, Masson S, et al
    The long-term prognosis of Alcoholic Hepatitis is poor and independent of disease severity for patients surviving an acute episode (Reply).
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30145.
    PubMed     Text format    


  66. SANDAHL TD, Vilstrup H, Jepsen P
    The long-term prognosis of Alcoholic Hepatitis is poor and independent of disease severity for patients surviving an acute episode.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30147.
    PubMed     Text format    


  67. WANG XC, Zhang XY, Zhang X, Yuan ZX, et al
    Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM(VCTE) algorithm.
    J Hepatol. 2018;68:602-603.
    PubMed     Text format    


  68. PETIT JM, Bouillet B, Loffroy R, Rouland A, et al
    Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes.
    J Hepatol. 2018;68:603-604.
    PubMed     Text format    


  69. BOURSIER J, de Ledinghen V, Leroy V, Cales P, et al
    Reply to: "Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM(VCTE) algorithm" and to "Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes".
    J Hepatol. 2018;68:605-606.
    PubMed     Text format    


    February 2018
  70. COENRAAD MJ, Porcher R, Bendtsen F
    Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: it takes three to tango.
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30124.
    PubMed     Text format     Abstract available


    January 2018
  71. TURCO L, Garcia-Tsao G, Magnani I, Bianchini M, et al
    Cardiopulmonary hemodynamics and c-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30011.
    PubMed     Text format     Abstract available


  72. THOMAS JA, Ramachandran P, Forbes SJ
    Studies of macrophage therapy for cirrhosis - from mice to men.
    J Hepatol. 2018 Jan 6. pii: S0168-8278(18)30002.
    PubMed     Text format    


    December 2017
  73. SCHWARZINGER M, Rehm J, Mallet V
    "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 30. pii: S0168-8278(17)32539.
    PubMed     Text format    


  74. ALAVI M, Law MG, Dore GJ
    Reply to: "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 29. pii: S0168-8278(17)32538.
    PubMed     Text format    


  75. CALDWELL S, Marchesini G
    Cryptogenic vs NASH-cirrhosis: The rose exists well before its name.
    J Hepatol. 2017 Dec 13. pii: S0168-8278(17)32488.
    PubMed     Text format    


  76. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    PubMed     Text format    


  77. RATZIU V
    A critical review of endpoints for non-cirrhotic NASH therapeutic trials.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32481.
    PubMed     Text format     Abstract available


  78. VAN VUGT JLA, Alferink LJM, Buettner S, Gaspersz MP, et al
    A Model including Sarcopenia Surpasses the MELD Score in Predicting Waiting List Mortality in Cirrhotic Liver Transplant Candidates.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32474.
    PubMed     Text format     Abstract available


    November 2017
  79. HARTL J, Ehlken H, Sebode M, Peiseler M, et al
    Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.
    J Hepatol. 2017 Nov 24. pii: S0168-8278(17)32445.
    PubMed     Text format     Abstract available


  80. LEE YH, Kim KJ, Yoo ME, Kim G, et al
    Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32448.
    PubMed     Text format     Abstract available


  81. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    PubMed     Text format     Abstract available


  82. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available


  83. TERZI E, Iavarone M, Pompili M, Veronese L, et al
    Contrast enhanced ultrasound identifies hepatocellular carcinoma in cirrhosis: a large multicenter retrospective study.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32428.
    PubMed     Text format     Abstract available


    October 2017
  84. MOHAMMED MS, Ferrier G, Abouda G, Corless L, et al
    Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32403.
    PubMed     Text format    


  85. CHOUDHARY NS, Saraf N, Soin AS
    Liver Transplantation for Grade 3 Acute on Chronic Liver Failure: Type of Organ Failure is Important.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32401.
    PubMed     Text format    


  86. ARTRU F, Louvet A
    Reply to <<Liver transplantation for grade 3 acute-on-chronic liver failure: type of organ failure is important>>.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32402.
    PubMed     Text format    


  87. D'AMICO G, Morabito A, D'Amico M, Pasta L, et al
    Clinical states of cirrhosis and competing risks.
    J Hepatol. 2017 Oct 27. pii: S0168-8278(17)32399.
    PubMed     Text format     Abstract available


  88. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available


  89. KIM G, Jang SY, Nam CM, Kang ES, et al
    Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32397.
    PubMed     Text format     Abstract available


  90. KIM KM, Han CY, Kim JY, Cho SS, et al
    Galpha12 overexpression induced by miR16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells.
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32388.
    PubMed     Text format     Abstract available


  91. GUSTOT T, Agarwal B
    Selected patients with acute-on-chronic liver failure grade 3 are not too sick to be considered for liver transplantation.
    J Hepatol. 2017;67:667-668.
    PubMed     Text format    


    September 2017
  92. GANDHI CR
    Hepatic stellate cell activation and pro-fibrogenic signals.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32068.
    PubMed     Text format    


  93. THABUT D, Pauwels A, Carbonell N, Remy AJ, et al
    Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32281.
    PubMed     Text format     Abstract available


  94. MOOKERJEE RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, et al
    Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].
    J Hepatol. 2017 Sep 8. pii: S0168-8278(17)32209.
    PubMed     Text format    


  95. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed     Text format    


  96. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed     Text format    


  97. GROSSI G, Loglio A, Facchetti F, Borghi M, et al
    Tenofovir alafenamide as a Rescue Therapy in a Cirrhotic HBV Patient with a Hystory of Fanconi Syndrome and Multidrug Resistance: A Case Report.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32260.
    PubMed     Text format     Abstract available


    August 2017
  98. SHARMA SA, Kowgier M, Hansen BE, Pieter Brouwer W, et al
    Toronto HCC Risk Index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.
    J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248.
    PubMed     Text format     Abstract available


  99. GARVEY P, Murphy N, Flanagan P, Brennan A, et al
    Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249.
    PubMed     Text format     Abstract available


  100. PASCASIO JM, Vinaixa C, Ferrer MT, Colmenero J, et al
    Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
    J Hepatol. 2017 Aug 22. pii: S0168-8278(17)32215.
    PubMed     Text format     Abstract available


  101. MAJUMDAR A, Bailey M, Kemp WM, Bellomo R, et al
    Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32198.
    PubMed     Text format     Abstract available


  102. THALHEIMER U, Giannelli V, Maimone S
    Non selective beta blockers in cirrhosis.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32194.
    PubMed     Text format    


  103. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Erratum to "Human liver regeneration in advanced cirrhosis is organized by the portal tree" [J Hepatol 66 (2017) 778-786].
    J Hepatol. 2017;67:430-436.
    PubMed     Text format    


    July 2017
  104. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    PubMed     Text format     Abstract available


  105. PIANO S, Tonon M, Vettore E, Stanco M, et al
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32151.
    PubMed     Text format     Abstract available


  106. ROBERTO C, Valeria R, Cristina N, Simona B, et al
    Gut-derived endotoxin stimulates factor viii secretion from endothelial cells. implications for hypercoagulability in cirrhosis.
    J Hepatol. 2017 Jul 14. pii: S0168-8278(17)32145.
    PubMed     Text format     Abstract available


  107. FICKERT P, Wagner M
    Biliary bile acids in hepatobiliary injury - What is the link?
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)32008.
    PubMed     Text format     Abstract available


  108. STENGEL S, Stallmach A, Richter K, Landrock A, et al
    Serum metabolic signatures in patients with overt hepatic encephalopathy.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32138.
    PubMed     Text format    


  109. WEISS N, Colsch B, Fenaille F, Junot C, et al
    Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: do we really face two different entities?
    J Hepatol. 2017 Jul 5. pii: S0168-8278(17)32140.
    PubMed     Text format    


    June 2017
  110. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed     Text format    


  111. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  112. ARTRU F, Louvet A, Ruiz I, Levesque E, et al
    Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32079.
    PubMed     Text format     Abstract available


  113. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32074.
    PubMed     Text format    


  114. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed     Text format    


  115. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    PubMed     Text format    


  116. KALAMBOKIS GN, Baltayannis G, Christodoulou D, Christou L, et al
    Beta adrenergic blockade and advanced cirrhosis: does it really improve survival in patients with acute-on-chronic liver failure?
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32064.
    PubMed     Text format    


    May 2017
  117. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Text format     Abstract available


  118. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed     Text format    


  119. SHIN WJ, Hwang GS
    Reply to: "Pressure volume curves in cirrhosis: more than meets the eye".
    J Hepatol. 2017 May 9. pii: S0168-8278(17)32010.
    PubMed     Text format    


  120. RIPOLL C, Yotti R, Banares R, Bermejo J, et al
    Pressure Volume Curves in Cirrhosis: more than meets the eye.
    J Hepatol. 2017 May 8. pii: S0168-8278(17)32006.
    PubMed     Text format    


  121. MRIDHA AR, Wree A, Robertson AAB, Yeh MM, et al
    NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    J Hepatol. 2017;66:1037-1046.
    PubMed     Text format     Abstract available


    April 2017
  122. BRITO-AZEVEDO A
    Carvedilol and survival in cirrhosis with ascites: a cognitive bias?
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30219.
    PubMed     Text format    


  123. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  124. HALLAGER S, Ladelund S, Weis N
    Methodological considerations when calculating person time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30218.
    PubMed     Text format    


  125. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  126. MOHS A, Kuttkat N, Reissing J, Zimmermann HW, et al
    Functional role of CCL5/RANTES for HCC progression during chronic liver disease.
    J Hepatol. 2017;66:743-753.
    PubMed     Text format     Abstract available


    March 2017
  127. PREZIOSI ME, Singh S, Valore EV, Jung CL, et al
    Mice lacking liver-specific beta-catenin develop steatohepatitis and fibrosis after iron overload.
    J Hepatol. 2017 Mar 21. pii: S0168-8278(17)30146.
    PubMed     Text format     Abstract available


  128. TACKE F
    Targeting hepatic macrophages to treat liver diseases.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30125.
    PubMed     Text format     Abstract available


    February 2017
  129. SINHA R, Lockman KA, Mallawaarachchi N, Robertson M, et al
    Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
    J Hepatol. 2017 Feb 14. pii: S0168-8278(17)30073.
    PubMed     Text format     Abstract available


  130. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


  131. NAKAGAWA R, Muroyama R, Saeki C, Goto K, et al
    miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30066.
    PubMed     Text format     Abstract available


  132. ZENG QL, Xu GH, Zhang JY, Li W, et al
    Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30060.
    PubMed     Text format     Abstract available


  133. TREBICKA J
    Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close?
    J Hepatol. 2017;66:442-450.
    PubMed     Text format     Abstract available


    January 2017
  134. BOURSIER J, de Ledinghen V, Leroy V, Anty R, et al
    A stepwise algorithm using a at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30007.
    PubMed     Text format     Abstract available


    December 2016
  135. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed     Text format    


  136. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed     Text format    


  137. WEISS E, Rautou PE, Fasseu M, Giabicani M, et al
    Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30741.
    PubMed     Text format     Abstract available


  138. ARROYO V, Moreau R
    Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis.
    J Hepatol. 2016 Dec 15. pii: S0168-8278(16)30577.
    PubMed     Text format    


  139. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  140. MONTAGNESE S, De Rui M, Angeli P, Amodio P, et al
    Neuropsychiatric Performance in Patients with Cirrhosis: Who is "Normal"?
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30698.
    PubMed     Text format     Abstract available


    November 2016
  141. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Human liver regeneration in advanced cirrhosis is organized by the portal tree.
    J Hepatol. 2016 Nov 29. pii: S0168-8278(16)30690.
    PubMed     Text format     Abstract available


  142. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  143. CENI E, Mello T, Polvani S, Vasseur-Cognet M, et al
    The orphan nuclear receptor COUP-TFII coordinates hypoxia-independent proangiogenic responses in hepatic stellate cells.
    J Hepatol. 2016 Nov 17. pii: S0168-8278(16)30650.
    PubMed     Text format     Abstract available


  144. REIBERGER T, Mandorfer M
    Beta adrenergic blockade and decompensated cirrhosis.
    J Hepatol. 2016 Nov 15. pii: S0168-8278(16)30647.
    PubMed     Text format     Abstract available


  145. JANJUA NZ, Chong M, Kuo M, Woods R, et al
    Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    J Hepatol. 2016 Nov 3. pii: S0168-8278(16)30637.
    PubMed     Text format     Abstract available


    October 2016
  146. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed     Text format    


  147. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  148. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed     Text format    


  149. DEUFFIC-BURBAN S, Boursier J, Leroy V, Yazdanpanah Y, et al
    Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    J Hepatol. 2016 Oct 12. pii: S0168-8278(16)30568.
    PubMed     Text format     Abstract available


  150. VAN DER MEER AJ, Berenguer M
    Reversion of disease manifestations after HCV eradication.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  151. MORADPOUR D, Grakoui A, Manns MP
    Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  152. YOUNOSSI ZM, Birerdinc A, Henry L
    Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


    September 2016
  153. CHAYANUPATKUL M, Omino R, Mittal S, Kramer JR, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2016 Sep 28. pii: S0168-8278(16)30540.
    PubMed     Text format     Abstract available


  154. SHIN WJ, Song JG, Jun IG, Moon YJ, et al
    Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations.
    J Hepatol. 2016 Sep 26. pii: S0168-8278(16)30536.
    PubMed     Text format     Abstract available


  155. FELIPO V, Montagnese S
    A rare and revealing glimpse of the cerebrospinal fluid of patients with hepatic encephalopathy.
    J Hepatol. 2016 Sep 24. pii: S0168-8278(16)30538.
    PubMed     Text format    


  156. DUCHE M, Ducot B, Ackermann O, Guerin F, et al
    Portal hypertension in children: High-risk varices, primary prophylaxis and consequences of bleeding.
    J Hepatol. 2016 Sep 20. pii: S0168-8278(16)30507.
    PubMed     Text format     Abstract available


  157. VENKATESH SK, Loomba R
    Editorial: Non-invasive estimation of HVPG by combined structural and hemodynamic evaluation of portal hypertension using quantitative magnetic resonance imaging.
    J Hepatol. 2016 Sep 20. pii: S0168-8278(16)30509.
    PubMed     Text format    


  158. KOO BK, Kim D, Joo SK, Kim JH, et al
    Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    J Hepatol. 2016 Sep 3. pii: S0168-8278(16)30484.
    PubMed     Text format     Abstract available


    August 2016
  159. ROMBOUTS K, Bemeur C, Rose CF
    Targeting the muscle for the treatment and prevention of hepatic encephalopathy.
    J Hepatol. 2016 Aug 30. pii: S0168-8278(16)30474.
    PubMed     Text format    


    July 2016
  160. MITTAL S, Kanwal F, Ying J, Chung R, et al
    Effectiveness of Surveillance for Hepatocellular Carcinoma in Clinical Practice: A United States cohort.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30395.
    PubMed     Text format     Abstract available


  161. PALANIYAPPAN N, Cox E, Bradley C, Scott R, et al
    Non-invasive assessment of Portal Hypertension Using Quantitative Magnetic Resonance Imaging.
    J Hepatol. 2016 Jul 27. pii: S0168-8278(16)30348.
    PubMed     Text format     Abstract available


  162. SCHUELLER F, Roy S, Trautwein C, Luedde T, et al
    miR-122 expression is not regulated during activation of hepatic stellate cells.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30308.
    PubMed     Text format    


  163. LI J, Li S
    Response to Letter to the Editor on comments on "miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. Li J, et al. J Hepatol 2013;58:522-528."
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30315.
    PubMed     Text format    


    June 2016
  164. VAN MEER S, Lieveld FI, van Erpecum KJ
    Patients' misconceptions about surveillance for hepatocellular carcinoma: Education is needed.
    J Hepatol. 2016 Jun 16. pii: S0168-8278(16)30274.
    PubMed     Text format    


  165. DULAI PS, Sirlin CB, SLoomba R
    MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30267.
    PubMed     Text format     Abstract available


    May 2016
  166. MANDORFER M, Kozbial K, Schwabl P, Freissmuth C, et al
    Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30238.
    PubMed     Text format     Abstract available


  167. HARTL J, Denzer U, Ehlken H, Zenouzi R, et al
    Validation of transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30209.
    PubMed     Text format     Abstract available


  168. JIAO J, Ooka K, Fey H, Fiel MI, et al
    Interleukin-15 Receptor alpha on Hepatic Stellate Cells Controls Fibrogenesis In Murine Liver Injury.
    J Hepatol. 2016 May 3. pii: S0168-8278(16)30164.
    PubMed     Text format     Abstract available


    April 2016
  169. LULI S, Di Paolo D, Perri P, Brignole C, et al
    A new fluorescence based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo.
    J Hepatol. 2016 Apr 8. pii: S0168-8278(16)30104.
    PubMed     Text format     Abstract available


  170. WESTBROOK RH, Dusheiko G, Williamson C
    Pregnancy and liver disease.
    J Hepatol. 2016;64:933-45.
    PubMed     Text format     Abstract available


    March 2016
  171. PETTA S, Valenti L, Marra F, Grimaudo S, et al
    MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:682-90.
    PubMed     Text format     Abstract available


  172. MOOKERJEE RP, Pavesi M, Thomsen KL, Mehta G, et al
    Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
    J Hepatol. 2016;64:574-82.
    PubMed     Text format     Abstract available


    February 2016
  173. ZAHND C, Salazar-Vizcaya L, Dufour JF, Mullhaupt B, et al
    Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00164.
    PubMed     Text format     Abstract available


  174. BALA S, Csak T, Saha B, Zatsiorsky J, et al
    The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00078.
    PubMed     Text format     Abstract available


  175. YOVCHEV MI, Locker J, Oertel M
    Biliary fibrosis drives liver repopulation and phenotype transition of transplanted hepatocytes.
    J Hepatol. 2016 Feb 5. pii: S0168-8278(16)00079.
    PubMed     Text format     Abstract available


  176. PIETRANGELO A
    Mechanisms of iron hepatotoxicity.
    J Hepatol. 2016 Feb 5. pii: S0168-8278(16)00080.
    PubMed     Text format    


  177. ESLAM M, Hashem AM, Romero-Gomez M, Berg T, et al
    FibroGENE: A gene-based model for staging liver fibrosis.
    J Hepatol. 2016;64:390-8.
    PubMed     Text format     Abstract available


    January 2016
  178. LUA I, Li Y, Zagory JA, Wang KS, et al
    Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers.
    J Hepatol. 2016 Jan 19. pii: S0168-8278(16)00015.
    PubMed     Text format     Abstract available


  179. CASTERA L
    Non-invasive tests for liver fibrosis progression and regression.
    J Hepatol. 2016;64:232-3.
    PubMed     Text format    


  180. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    PubMed     Text format     Abstract available


  181. KARSDAL MA, Genovese F, Madsen EA, Manon-Jensen T, et al
    Collagen and tissue turnover as a function of age: Implications for fibrosis.
    J Hepatol. 2016;64:103-9.
    PubMed     Text format     Abstract available


  182. JIANG M, Klein M, Zanger UM, Mohammad MK, et al
    Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease.
    J Hepatol. 2016;64:44-52.
    PubMed     Text format     Abstract available


    November 2015
  183. PAGE A, Paoli P, Moran Salvador E, White S, et al
    Hepatic Stellate Cell Transdifferentiation Involves Genome-Wide Remodeling of the DNA Methylation Landscape.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00782.
    PubMed     Text format     Abstract available


  184. RAY KIM W, Berg T, Asselah T, Flisiak R, et al
    Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770.
    PubMed     Text format     Abstract available


  185. EGUCHI A, Jeu XM, Johnson CD, Nektaria A, et al
    Liver Bid-suppression for treatment of fibrosis associated with nonalcoholic steatohepatitis.
    J Hepatol. 2015 Nov 7. pii: S0168-8278(15)00732.
    PubMed     Text format     Abstract available


    October 2015
  186. ORO D, Yudina T, Fernandez-Varo G, Casals E, et al
    Cerium oxide nanoparticles reduce steatosis, portal hypertension and display antiinflammatory properties in rats with liver fibrosis.
    J Hepatol. 2015 Oct 28. pii: S0168-8278(15)00719.
    PubMed     Text format     Abstract available


  187. CHUNG SI, Moon H, Ju HL, Cho KJ, et al
    Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model.
    J Hepatol. 2015 Oct 12. pii: S0168-8278(15)00678.
    PubMed     Text format     Abstract available


    August 2015
  188. LEI XF, Fu W, Kim-Kaneyama JR, Omoto T, et al
    Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00598.
    PubMed     Text format     Abstract available


    July 2015
  189. ZHENG Z, Zhang X, Wang J, Dandeka A, et al
    Exposure to Fine Airborne Particulate Matters Induces Hepatic Fibrosis in Murine Models.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00511.
    PubMed     Text format     Abstract available


  190. EL-SHAMY A, Eng FJ, Doyle EH, Klepper AL, et al
    A Cell Culture System for Distinguishing Hepatitis C Viruses with and without Liver Cancer-related Mutations in the Viral Core Gene.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00515.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: